Novo Nordisk Makes Executive Changes

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-22-2017 16:15


Novo Nordisk has made changes to its executive management team by promoting two senior vice presidents to the position of executive vice president.

Camilla Sylvest, senior vice president in charge of Novo Nordisk's operations in Region China, has been appointed executive vice president in charge of commercial strategy and corporate affairs. She will have overall responsibility for the company's corporate functions within marketing, market access, strategy, communication, stakeholder relations, and sustainability.

Sylvest was appointed senior vice president and general manager of Novo Nordisk's Region China in August 2015. In this role, she was responsible for the company's activities in China, Taiwan, and Hong Kong. She started her career in Novo Nordisk in 1996, and followed with roles in headquarters and regions within pricing, health economics, marketing, and sales effectiveness.

Effective August 15 2017, Doug Langa, senior vice president, head of North American operations and president of Novo Nordisk Inc., is promoted to executive vice president. His responsibilities remain unchanged.

Doug Langa was appointed head of North American operations and president of Novo Nordisk Inc. in March 2017. Previously, he was senior vice president of Market Access (Novo Nordisk) and a member of Novo Nordisk's US leadership team. He joined the company in 2011 and has over 25 years of experience in the pharmaceutical and medical-device industry.

Both Sylvest and Langa will report to Lars Fruergaard Jorgensen, CEO of Novo Nordisk.  

Source: Novo Nordisk


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription